Scientific paper - Original scientific paper
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
The Lancet Diabetes & Endocrinology, 11 (2023), 10; 720-730. https://doi.org/10.1016/S2213-8587(23)00193-6

Terzolo, Massimo; Fassnacht, Martin; Perotti, Paola; Libe, Rossella; Kaštelan, Darko; Lacroix, Andre; Arlt, Wiebke; Haak, Haram Reinout; Loli, paola; Decoudier, Benedicte; Lasolle, Helene; Quinkler, Marcus; Haissaguerre, Magalie; Chabre, Olivier; Caron, Philippe; Stigliano, Antonio; Giordano, Roberta; Zatelli, Maria Chiara; Bancos, Irina; Fragoso, Maria Candida Barisson Villares; Canu, Letizia; Luconi, Michaela; Puglisi, Soraya; Basiel, Vittoria; Reimondo, Giuseppe; Kroiss, Matthias; Megerle, Felix; Hahner, Stefanie; Kimpel, Otilia; Dušek, Tina; Nölting, Svenja; Bourdeau, Isabelle; Baudin, Eric; Berchialla, Paola; Bovis, Francesca; Sormani, Maria Pia; Bruzzi, Paolo; Beuschlein, Felix; Bertherat, Jerome; Berruti, Alfredo More authors...

Cite this document

Terzolo, M., Fassnacht, M., Perotti, P., Libe, R., Kaštelan, D., Lacroix, A. ... Berruti, A. (2023). Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. The Lancet Diabetes & Endocrinology, 11. (10), 720-730. doi: 10.1016/S2213-8587(23)00193-6

Terzolo, Massimo, et al. "Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study." The Lancet Diabetes & Endocrinology, vol. 11, no. 10, 2023, pp. 720-730. https://doi.org/10.1016/S2213-8587(23)00193-6

Terzolo, Massimo, Martin Fassnacht, Paola Perotti, Rossella Libe, Darko Kaštelan, Andre Lacroix, Wiebke Arlt, et al. "Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study." The Lancet Diabetes & Endocrinology 11, no. 10 (2023): 720-730. https://doi.org/10.1016/S2213-8587(23)00193-6

Terzolo, M., et al. (2023) 'Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study', The Lancet Diabetes & Endocrinology, 11(10), pp. 720-730. doi: 10.1016/S2213-8587(23)00193-6

Terzolo M, Fassnacht M, Perotti P, Libe R, Kaštelan D, Lacroix A, and sur.. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. The Lancet Diabetes & Endocrinology [Internet]. 2023 October [cited 2024 October 07];11(10):720-730. doi: 10.1016/S2213-8587(23)00193-6

M. Terzolo, et al., "Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study", The Lancet Diabetes & Endocrinology, vol. 11, no. 10, pp. 720-730, October 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:260017. [Accessed: 07 October 2024]

Please login to the repository to save this object to your list.